1. Hansen IS, Krabbendam L, Bernink JH, Loayza-Puch F, Hoepel W, van Burgsteden J, Kuijper EC, Buskens CJ, Bemelman WA, Zaat SAJ, Agami R, Vidarsson G, van den Brink   GR, de Jong EC, Wildenberg ME, Baeten DLP, Everts B, den Dunnen J. FcαRI co- stimulation converts human intestinal CD103+ dendritic cells into pro-inflammatory cells through glycolytic reprogramming. Nature Communications: 28;9(1):863 (2018) [Pubmed]

  2. Li L, van Breugel PC, Loayza-Puch F, Ugalde AP, Korkmaz G, Messika-Gold N, Han R, Lopes R, Barbera EP, Teunissen H, de Wit E, Soares RJ, Nielsen BS, Holmstrøm K, Martínez-Herrera DJ, Huarte M, Louloupi A, Drost J, Elkon R, Agami R. LncRNA-OIS1 regulates DPP4 activation to modulate senescence induced by RAS. Nucleic Acids Research: 4;46(8):4213-4227 (2018) [Pubmed]

  3. Gao F, Wesolowska M, Agami R, Rooijers K3, Loayza-Puch F, Lawless C, N Lightowlers R, M A Chrzanowska-Lightowlers Z. Using mitoribosomal profiling to investigate human mitochondrial translation. Wellcome Open Research: 11;2:116 (2017) [Pubmed]

  4. Loayza-Puch F#,Rooijers K, Zijlstra J, Moumbeini B, Zaal EH, Vrielink JAF, Lopes R, Ugalde AP, Berkers CR, Agami R#. TGF-beta-1-induced leucine limitation uncovered by differential ribosome codon reading. EMBO Reports: 18(4):549-557 (2017) [Pubmed]

  5. Slobodin B, Han R, Calderone V, Oude Vrielink J, Loayza-Puch F, Elkon R, Agami R. Transcription Impacts the Efficiency of mRNA Translation via Co-transcriptional N6-adenosine Methylation.Cell:169(2):326-337 (2017) [Pubmed]

  6. Loayza-Puch F#and Agami R#: Monitoring amino acid deficiencies in cancer. Cell Cycle: 31, 1-2 (2016) [Pubmed]

  7. Loayza-Puch F*, Rooijers K*, Buil L, Zijlstra J, Oude Vrielink JAF, Lopes R, Ugalde AP, van Breugel P, Bex A, Hofland I, Wesseling I, van Tellingen O, Agami R: Tumour-specific proline vulnerability uncovered by differential ribosome codon reading. Nature:530, 490–494 (2016) [Pubmed]

  8. Drost R, Dhillon KK, van der Gulden H, van der Heijden I, Brandsma I, Cruz C, Chondronasiou D, Castroviejo-Bermejo M, Boon U, Schut E, van der Burg E, Wientjens E, Pieterse M, Klijn C, Klarenbeek S, Loayza-Puch F, Elkon R, van Deemter L, Rottenberg S, van de Ven M, Dekkers DH, Demmers JA, van Gent DC, Agami R, Balmaña J, Serra V, Taniguchi T, Bouwman P, Jonkers J. BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1. Journal of Clinical Investigation: 126(8):2903-18 (2016) [Pubmed]

  9. Elkon R*, Loayza-Puch F*,Korkmaz G, Lopes R, van Breugel P, Bleijerveld O, Altelaar AFM, Wolf E, Lorenzin F, Eilers M, Agami R: Myc coordinates transcription and translation to enhance transformation and suppress invasiveness. EMBO Reports: 16: 1723-1736 (2015) [Pubmed]

  10. Konovalova S, Hilander T, Loayza-Puch F, Rooijers K, Agami R, Tyynismaa H. Exposure to arginine analog canavanine induces aberrant mitochondrial translation products, mitoribosome stalling, and instability of the mitochondrial proteome. Int J Biochem Cell Biol: 65:268-74 (2015) [Pubmed]

  11. Rooijers K*, Loayza-Puch F*, Nijtmans L, Agami R: Ribosome profiling reveals features of normal and disease-associated mitochondrial translation. Nature Communications: 2:2886 (2013) [Pubmed]

  12. Loayza-Puch Fand Agami R: Lncing protein translation to metastasis. EMBO journal: 16;32(20):2657-8. (2013) [Pubmed]

  13. Loayza-Puch F, Drost J, Rooijers K, Lopes R, Elkon R, Agami R: p53 induces transcriptional and translational programs to suppress cell proliferation and growth. Genome Biology: 14:R32 (2013) [Pubmed]

  14. Jenal M*, Elkon R*, Loayza-Puch F*, van Haaften G, Kuhn U, Menzies FM, Vrielink JA, Bos AJ, Drost J, Rooijers K et al: The poly(a)-binding protein nuclear 1 suppresses alternative cleavage and polyadenylation sites. Cell: 149(3):538-553 (2012) [Pubmed]

  15. Gomez-Benito M, Loayza-Puch F, Oude Vrielink JAF, Odero MD, Agami R. 3′UTR-Mediated Gene Silencing of the Mixed Lineage Leukemia (MLL) Gene. Plos One:6(10) e25449 (2011) [Pubmed]

  16. Loayza-Puch F, Yoshida Y, Matsuzaki T, Takahashi C, Kitayama H, Noda M. Hypoxia and RAS-signaling pathways converge on, and cooperatively downregulate, the RECK tumor-suppressor protein through microRNAs. Oncogene:29: 2638-2648. (2010) [Pubmed]

to top